This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cerus To Partner With American Red Cross And Blood Systems Incorporated To Commercialize INTERCEPT Plasma For Thrombotic Thrombocytopenic Purpura (TTP) Orphan Indication

This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to the potential launch and commercialization of, and potential approval by the FDA of, INTERCEPT-treated plasma to treat TTP, potential orphan drug exclusivity for INTERCEPT-treated plasma to treat TTP if approved by the FDA, the commercial potential for INTERCEPT-treated plasma to treat TTP, and Cerus’ expectations regarding the success and significance of the BSI and American Red Cross partnerships. These forward-looking statements are based upon Cerus’ current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with the uncertain, costly and time-consuming product development process, risks associated with obtaining FDA regulatory approval for INTERCEPT-treated plasma, risks related to the commercial prospects for INTERCEPT-treated plasma, the risks that Cerus, the American Red Cross and BSI may not fulfill their respective obligations under the partnership agreements or that the partnership agreements may not be maintained, risks related to Cerus’ need for additional capital, including the risk that the sufficient additional funding Cerus requires for the further development of INTERCEPT-treated plasma for approval in the US may not be obtained, and other risks detailed in the Cerus' filings with, the Securities and Exchange Commission (SEC), including in Cerus' annual report on Form 10-Q for the quarter ended June 30, 2012, filed with the SEC on August 8, 2012. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Cerus does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.

Copyright Business Wire 2010
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,265.29 +206.94 1.29%
S&P 500 1,937.37 +23.52 1.23%
NASDAQ 4,707.6020 +71.4970 1.54%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs